Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 12/20 | 0.66 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.52 |
| ▸ | HRH1 | P35367 | 3/20 | 0.52 |
| ▸ | HRH2 | P25021 | 2/20 | 0.52 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 4/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2167537 | 1.00 | HRH4 (0.66) | HRH4HRH3HRH1HRH2BCHE | |
| SCHEMBL14084002 | 0.91 | HRH4 (0.71) | HRH4HRH3HRH1HRH2BCHE | |
| SCHEMBL14084005 | 0.91 | HRH4 (0.71) | HRH4HRH3HRH1HRH2BCHE | |
| SCHEMBL14084007 | 0.90 | HRH4 (0.64) | HRH4HRH3HRH1HRH2BCHE | |
| SCHEMBL2166385 | 0.89 | HRH4 (0.63) | HRH4HRH3HRH1HRH2BCHE | |
| SCHEMBL606390 | 0.88 | HRH4 (0.70) | HRH4HRH3HRH1HRH2BCHE | |
| SCHEMBL14084037 | 0.84 | HRH4 (0.74) | HRH4HRH3HRH1HRH2BCHE | |
| SCHEMBL14084019 | 0.84 | HRH4 (0.70) | HRH4HRH3HRH1HRH2BCHE | |
| SCHEMBL606346 | 0.83 | HRH4 (0.67) | HRH4HRH3HRH1HRH2BCHE | |
| SCHEMBL14084054 | 0.83 | HRH4 (0.68) | HRH4HRH3HRH1HRH2BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735411-B2 | Macrocyclic benzofused pyrimidine derivatives | ABBVIE INC. (US) | 2014-05-27 | — | — | US | claimed |
| US-7985745-B2 | Including inflammatory pain, post surgical pain, and neuropathic pain; administering a histamine H4 receptor ligand alone or in combination with a histamine H1, H2, or H3 receptor antagonist or an enzyme inhibitor | ABBOTT LABORATORIES (US) | 2011-07-26 | — | — | US | claimed |
| US-20080188452-A1 | Macrocyclic Benzofused Pyrimidine Derivatives | ABBVIE INC. | 2008-08-07 | — | — | US | claimed |
| US-8735411-B2 | Macrocyclic benzofused pyrimidine derivatives | ABBVIE INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-7985745-B2 | Including inflammatory pain, post surgical pain, and neuropathic pain; administering a histamine H4 receptor ligand alone or in combination with a histamine H1, H2, or H3 receptor antagonist or an enzyme inhibitor | ABBOTT LABORATORIES (US) | 2011-07-26 | — | — | US | disclosed |
| US-20080194538-A1 | Method for Pain Treatment | ABBVIE INC. | 2008-08-14 | — | — | US | disclosed |
| US-20080188452-A1 | Macrocyclic Benzofused Pyrimidine Derivatives | ABBVIE INC. | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188452-A1 | Macrocyclic Benzofused Pyrimidine Derivatives | DPYD, TYMS, UMPS | HRH4 3013/4885HRH3 3492/4885HRH1 2660/4885 |
| US-20080194538-A1 | Method for Pain Treatment | HRH4, HRH3, HRH2 | HRH4 1/4885HRH3 2/4885HRH1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.